Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Rashid, Waqar Ciccarelli, Olga Leary, Siobhan M Doshi, Anisha Evangelou, Nikos Ford, Helen L Hobart, Jeremy Jacob, Saiju Muraro, Paolo Antonio
Rashid, Waqar
Ciccarelli, Olga
Leary, Siobhan M
Doshi, Anisha
Evangelou, Nikos
Ford, Helen L
Hobart, Jeremy
Jacob, Saiju
Muraro, Paolo Antonio
Abstract
The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2024-11-11
Type
Article
Other
Other
Subject
Collections
Citation
Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA, Murray K, Palace J, Dobson R; Association Of British Neurologists Multiple Sclerosis and Neuroinflammation Advisory Group. Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. Pract Neurol. 2025 Jan 16;25(1):18-24. doi: 10.1136/pn-2024-004228.